I

n the latest effort to respond to criticism over drug pricing, Sanofi says it will limit price hikes to a level at or below the medical rate of inflation in the US, which is projected to reach 5.4 percent this year. And like other companies, the drug maker released recent price increases — before and after rebates paid to middlemen —and vowed to continue doing so in the future.

“Beyond hindering access for patients to critical innovations, th[e] complexity [in the pricing system] is undermining the reputation of an entire industry whose purpose is to make a positive change in patients’ lives,” Sanofi chief executive Olivier Brandicourt wrote on the company web site in announcing the new policy on Tuesday. He acknowledged there may be exceptions to the stated policy, though.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.